NIK SMI1 - 98%, high purity , CAS No.1660114-31-7, Inhibitor of leucine rich repeat kinase 2;Inhibitor of mitogen-activated protein kinase kinase kinase 14;Inhibitor of mitogen-activated protein kinase kinase kinase kinase 5;Inhibitor of protein kinase D1

Item Number

N414283

• Synonyms: (R)-6-(3-((3-Hydroxy-1-methyl-2-oxopyrrolidin-3-yl)-ethynyl)phenyl)-4-methoxypicolinamide, 6-[3-[2-[(3R)-3-Hydroxy-1-methyl-2-oxo-3-pyrrolidinyl]ethynyl]phenyl]-4-methoxy-2-pyridinecarboxamide, NIK small molecule inhibitor 1
• Specifications & Purity: Moligand™, ≥98%
• Biochemical and Physiological Mechanisms: NIK SMI1 is a highly potent and selective NF-κB-inducing kinase (NIK) inhibitor with Ki of 0.23 nM for NIK-catalyzed hydrolysis of ATP to ADP.NIK SMI1 is an orally active, ATP site-targeting, potent and selective NF-κB-inducing kinase inhibitor (h/m NIK I
• Storage Temp: Store at -20°C
• Shipped In: Ice chest + Ice pads
• Grade: Moligand™
• Action Type: INHIBITOR
• Mechanism of action: Inhibitor of leucine rich repeat kinase 2;Inhibitor of mitogen-activated protein kinase kinase kinase 14;Inhibitor of mitogen-activated protein kinase kinase kinase kinase 5;Inhibitor of protein kinase D1

Product Description

Information

NIK SMI1 NIK SMI1 is a highly potent and selective NF-κB-inducing kinase (NIK) inhibitor with Ki of 0.23 nM for NIK-catalyzed hydrolysis of ATP to ADP.

Targets

NIK-catalyzed hydrolysis of ATP to ADP 0.23 nM(Ki)

In vitro

NIK SMI1 exhibits selective inhibition of LTβR-dependent p52 translocation and transcription of NF-κB2 related genes. NIK SMI1 is shown to have a favorable pharmacokinetic profile across species and to inhibit BAFF-induced B cell survival in vitro.

In vivo

NIK SMI1 inhibits BAFF signaling and reduces splenic marginal zone B cells in vivo.

Cell Research(from reference)

Cell lines：293 cells, HeLa cells, SF9 cell line, Human B cells, Mouse B cells 

Concentrations：1 μM, different concentrations 

Incubation Time：24 h, 5 h